---
document_datetime: 2025-09-26 16:57:44
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ibandronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ibandronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 21.1765497
conversion_datetime: 2025-12-17 07:18:23.880126
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Ibandronic acid Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthecompleteproductlifecycleprocedures,youmayneedtoalsorefertoEPAR-Proceduralstepstakenandscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ² / amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.ADMINISTRATIVECHANGES-A.7 | 25/09/2025                          |                                           | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex Il, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (Eu) No. 712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000300801                   | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place,or supplier of a starting material, reagentorexcipient(whenmentionedinthe dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     | PL   |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation typeIB/ EMA/VR/0000285794 | Thiswas an applicationforagroupof variations. B.1.b.2Changeintestprocedurefor active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance-B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minorchange to therestrictedpartof an ActiveSubstanceMasterFile-Accepted A.ADMINISTRATIVE CHANGES-A.4 Change in the name and/or address of: a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive substance(where specified in the technical | 23/09/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substance - B.I.c.2.b Addition of a new specification parameter to the specification with its corresponding test method - Accepted                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I.b.1 Changein thespecification parameters and/or limits of an active substance,startingmaterial/intermediate/ reagent used in the manufacturing process of theactive substance-B.I.b.1.cAddition of anewspecificationparameter to the specification with its corresponding test method-Accepted                                                                                                     |
| B.II.2 Change to comply with Ph. Eur. or with anational pharmacopoeia of aMember State - B.1II.2.b Change to comply with an update of the relevant monograph of the Ph. Eur.ornational pharmacopoeiaof a Member State - Accepted B.III.2 Change tocomplywithPh.Eur.or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. |
| Eur.ornational pharmacopoeia of a Member                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                       | State - Accepted B.II1.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.llI.2.b Change to comply with an update of the relevant monograph of the Ph. Eur.or national pharmacopoeia of aMember State - Accepted B.II1.2 Change to comply with Ph. Eur. or withanationalpharmacopoeiaofaMember State-B.III.2.bChange tocomplywith an updateof therelevantmonographof thePh. Eur.ornationalpharmacopoeiaofaMember State - Accepted B.II1.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.llI.2.b Change to comply with an updateoftherelevantmonographofthePh. Eur.ornational pharmacopoeiaof aMember State - Accepted   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000249358 | C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (IB) -To provide a new RMP version                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| to update the safety concerns according to the reference product, as follows: -Addition of\"Atypical fractures of long bones\"as an important identified risk. -Removal of \"Atypical femoral fracture\" as an important potential risk.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|